Peripheral Vascular Devices Market is Expected to Reach an Estimated US$ 16.83 Million with a CAGR of 4.5% by 2033 |Fact.MR

According to a recent industry report by Fact.MR, a market research and competitive intelligence provider, global sales of peripheral vascular devices are predicted to grow at a 4.5% CAGR from 2023 to 2033, reaching a market value of US$ 16.83 million by the end of the forecast period.

Peripheral vascular disorder (PVD) is defined as the formation of atherosclerotic plaque in the arteries that provide blood to bodily organs such as the limbs and head. PVD is also known as peripheral artery occlusive disease (PAOD), peripheral artery disease (PAD), or peripheral obliterative arteriopathy. It encompasses conditions that affect the body's peripheral and cardiac circulation, which includes both peripheral arteries and veins.

Angioplasty stents, angioplasty balloon catheters, endovascular aneurysm repair (EVAR) stent-grafts, plaque modification devices, hemodynamic flow alteration devices, and inferior vena cava filters are examples of peripheral vascular devices used to treat peripheral arterial diseases, as well as coronary and endovascular treatment procedures.

Peripheral vascular devices are utilized to eliminate patient interference during surgeries while causing minimal disturbance. The rising prevalence of venous diseases, also known as CVI (Chronic Venous Insufficiency), is expected to fuel growth in the global market for peripheral vascular devices. Furthermore, the growing global elderly population is increasing the incidence of heart illnesses, which is driving sales of peripheral vascular devices.

Download Sample Copy of This Report -
https://www.factmr.com/connectus/sample?flag=S&rep_id=8329

Key Takeaways from Market Study

By 2023, the global market for peripheral vascular devices is expected to be worth $10.84 billion.
Global sales of angioplasty stents are predicted to grow at a 5% CAGR through 2033.
Global demand for angioplasty balloon catheters is expected to grow at a CAGR of 4% over the next ten years.
The market for peripheral vascular devices in Japan is expected to grow at a 4% CAGR over the forecast period.

Competitive Landscape

To enhance and retain their market position, prominent companies in the peripheral vascular devices market are creating improved devices. Market participants use a variety of marketing strategies, including mergers and acquisitions, collaborations, new product developments, and the improvement of local supply management systems.

In September 2021, Abbott announced the acquisition of Walk Vascular, an LLC, a medical device manufacturer that produces a minimally invasive mechanical aspiration peripheral venous thrombectomy device for the removal of peripheral blood clots. Abbott has incorporated Walk Vascular's peripheral thrombectomy systems into its current endovascular product range. Abbott's peripheral vascular device and accessory portfolio was broadened as a result of the collaboration.
Cardio Flow, Inc., a manufacturer of minimally invasive peripheral vascular devices used to treat peripheral artery disease, announced in June 2022 that the FreedomFlow Peripheral Guidewire has obtained FDA approval.

Key Companies Profiled

Abbott Laboratories
B. Braun Melsungen AG
BARD, A Becton, Dickinson Company
Biosensors International Group Ltd.
Biotronik SE & Co. KG
Boston Scientific Corporation
Cordis Corporation
iVascular S.L.U
Medtronic PLC
Terumo Corporation

Get Customization on this Report for Specific Research Solutions -
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8329

Recent Developments

Cordis, a worldwide cardiovascular technology company, announced that the S.M.A.R.T. RADIANZ Vascular Stent System, a self-expanding stent designed specifically for radial peripheral treatments, will be approved by the FDA in March 2022. This device was designed specifically to improve radial access, produce excellent results, and increase patient satisfaction.
In October 2021, Boston Scientific Corporation announced positive clinical trial data for the Eluvia Drug-Eluting Vascular Stent System at the Vascular InterVentional Advances (VIVA) conference in Las Vegas. According to the EMINENT study, the Eluvia stent outperformed self-expanding bare metal stents in treating patients with superficial femoral artery (SFA) lesions up to 210 mm in length and peripheral arterial disease. With 775 patients taking part, it was the largest drug stent randomized trial for the treatment of PAD to date.
In January 2022, the US Food and Drug Administration (FDA) granted Cook Medical breakthrough device status for a unique drug-eluting stent for below the knee (BTK). This novel stent is intended to treat patients with persistent ischemia that poses a risk to their limbs.

Key Segments of Peripheral Vascular Devices Industry Research

By Type :
Angioplasty Stents
Angioplasty Balloon Catheters
Endovascular Aneurysm Repair (EVAR) Stent Grafts
Plaque Modification Devices
Hemodynamic Flow Alteration Devices
Inferior Vena Cava Filters
By Indication :
Target Artery Instabilities (TAIs)
Access Artery Injuries (AAIs)
Peripheral Arterial Diseases
Arteriovenous Fistulas
Peripheral Aneurysms
By End User :
Hospitals
Ambulatory Surgical Centers
Cardiac Catheterization Labs
By Region :
North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA

Full Access of Complete Report Is Available -
https://www.factmr.com/report/peripheral-vascular-devices-market

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global peripheral vascular devices market, presenting historical demand data for 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study divulges essential insights on the market on the basis of type (angioplasty stents, angioplasty balloon catheters, endovascular aneurysm repair (EVAR) stent-grafts, plaque modification devices, hemodynamic flow alteration devices, inferior vena cava filters), indication (target artery instabilities (TAIs), access artery injuries (AAIs), peripheral arterial diseases, arteriovenous fistulas, peripheral aneurysms), and end user (hospitals, ambulatory surgical centers, cardiac catheterization labs), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.